No Surprises Act IDR Awards Reached an Estimated 0.6% of Individual Market Claims in 2025

What Individual Market Actuaries Should Consider as They Develop 2028 Premium Rates

Wakely’s new analysis estimates that Federal Independent Dispute Resolution (IDR) payment awards in the Individual Market equaled approximately 0.6% of national allowed claims in 2025. An estimated 0.5% of allowed claims represented payment above comparable in-network reimbursement levels.

The Individual Market accounted for an estimated 3.7% of Federal IDR disputes during the period analyzed. Yet Wakely estimates that total Individual Market IDR payment awards increased by more than 800% in 2025 compared with 2024. This white paper examines what these estimates may mean for premium pricing, claims reserves, financial reporting, risk adjustment, reinsurance, and provider negotiations.

DOWNLOAD NOW

Key Findings

  • Estimated national impact: In 2025, Individual Market IDR payment awards were equivalent to approximately 0.6% of national allowed claims. Awards above the Qualifying Payment Amount (QPA) were equivalent to approximately 0.5%.
  • Rapid year-over-year growth: Estimated Individual Market payment award dollars increased by more than 800% in 2025 compared with 2024.
  • State variation: Estimated payment awards exceeded 1% of state-specific allowed claims in Arizona, Texas, and New York. Arizona was estimated at 3.1%, Texas at 2.7%, and New York at 1.0%.
  • Potential costs beyond awards: IDR-related financial pressure may also include administrative fees and operational expenses, delayed claim development, effects on reinsurance recovery and risk adjustment, and potential changes to in-network reimbursement.
  • A 2028 pricing question: Actuaries should assess whether their experience period captures ultimate IDR liabilities and whether historical experience reflects emerging costs and forthcoming changes to the process.

What the White Paper Covers

The No Surprises Act protects people with employer-sponsored and Individual Marketplace coverage from certain unexpected out-of-network bills. When a provider and health plan cannot agree on payment for an eligible service, either party may take the dispute to the Federal IDR process. The IDR entity selects one party’s offer as the prevailing offer.

This white paper focuses on the Individual Market, a segment with less published analysis of NSA-related reimbursement costs. It estimates historical Federal IDR payment awards and awards above the QPA, compares those estimates with allowed claims, identifies states with greater estimated exposure, and considers implications for future premium rates.

This white paper also reviews how the IDR process may affect:

  • Claims reserves, claims completion, Medical Loss Ratio reporting, and year-end financial reporting
  • Risk adjustment transfers and reinsurance recoveries
  • In-network reimbursement negotiations and network adequacy
  • Administrative expenses, IDR entity fees, and operational workload
  • 2028 premium rate development in light of litigation, rule changes, proposed legislation, and IDR entity changes

What Should Actuaries Consider for 2028 Rates?

This white paper outlines questions for pricing actuaries, including whether base-period claims include ultimate IDR payments, how exposure may have changed since the experience period, whether QPA methodology changes could affect future payments, whether risk adjustment or reinsurance assumptions account for delayed claim resolution, and whether administrative and operational costs are reflected in projected expenses.

It also considers the possibility that provider success in IDR may affect network negotiations, reimbursement costs, and network adequacy—particularly in states with higher estimated IDR exposure.

Methodology and Limitations

Wakely used Centers for Medicare & Medicaid Services (CMS) Federal IDR Public Use File data from Q1 2023 through Q4 2025, along with Unified Rate Review Template and CMS Risk Adjustment Report data, to estimate Individual Market IDR payment awards and compare them with allowed claims.

CMS data do not directly identify health plan type or state in all relevant tables. Wakely therefore applied adjustments to estimate Individual Market and state-level results. The analysis also compares IDR data organized by service location and resolution date with market claims data that generally reflect member residence and incurred periods. Estimated 2024–2025 allowed claims and long IDR settlement lags add uncertainty to the results.

These figures are estimates and may not represent actual Individual Market IDR costs for every issuer or state. The report describes the data, methodology, and limitations in detail, including in Appendix A.

Frequently Asked Questions

What does Wakely estimate about Federal IDR costs in the Individual Market?

Wakely estimates that 2025 Individual Market IDR payment awards equaled approximately 0.6% of national allowed claims. Awards above the QPA were equivalent to approximately 0.5% of allowed claims.

Which states had the highest estimated Individual Market IDR exposure?

In 2025, estimated payment awards as a percentage of state-specific allowed claims were highest in Arizona at 3.1%, Texas at 2.7%, and New York at 1.0%. The report cautions that state-level estimates have important data limitations.

Does the report measure all costs associated with the IDR process?

No. The analysis estimates reimbursement payment awards and does not include administrative expenses, operational burden, or fees paid to IDR entities. It also notes that awards alone may not reflect all health plan costs associated with eligible claims.

How might the IDR process affect 2028 Individual Market premiums?

IDR exposure may affect direct reimbursement costs and expenses associated with participating in the process. Delayed resolutions may also affect claims reserves, financial reporting, risk adjustment, and reinsurance recoveries. The report recommends that actuaries evaluate whether experience and projection assumptions account for these potential effects.

What data years does the analysis include?

The analysis uses CMS Federal IDR Public Use File data from Q1 2023 through Q4 2025, the most recent data available to the authors when the report was written.

DOWNLOAD NOW

Sign up for the
Wakely Wire,
our industry newsletter.

Get news on the latest healthcare market trends, policy and regulatory developments, and more, sent straight to your inbox.

Sign Up Now
Questions? Let's Connect